Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs

Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Company’s Scientific Advisory Board.

Dr. Banerji joins internationally renowned opinion leaders including Dr. Santosh Kesari, Chair of Department of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute, Dr. Francesco Marincola, Global Head of Cell Therapy Research at Kite Therapeutics (owned by Gilead), Dr. Boris Minev, President of Calidi Biotherapeutics, and Dr. Boris Reznik, Chairman of Venvalo Group.

“I am pleased to welcome Dr. Banerji to our Scientific Advisory Board. His addition is perfectly timed as the Company is conducting a Phase III clinical trial in advanced COVID-19 patients¹ and has recently filed an Investigational New Drug Application (IND) for treatment of Chronic Obstructive Pulmonary Disease (COPD)²,^” said Timothy Dixon, President and Chief Executive Officer of the Company. “Our transition from a preclinical to a clinical stage organization requires domain-specific expertise and insight. Given that Dr. Banerji has obtained FDA approval for commercialization of 14 novel drugs in respiratory medicine, we believe his expertise is second to none.”

“Success in the area of regenerative medicine requires deep knowledge of the complicated scientific, biological and clinical issues associated with developing a ‘living drug’. I look forward to leveraging my previous experiences and contacts in the area of respiratory medicine to accelerate the progress of the Company in making an impact in the areas of COVID-19 and COPD, for which currently no regenerative approaches exist,” said Dr. Banerji.

Dr. Banerji is a Physician-Scientist with 33 years of Global Development and management experience in Pulmonary Drug Development, has led approvals and launch of 14 FDA approved drugs worldwide in COPD, Asthma and Allergic Rhinitis. Dr. Banerji has published over 100 original articles (The Ultibro story!) in peer reviewed journals (FLAME:NEJM) and over 400 abstracts, with presentations at major International Congress's. The recipient of multiple Novartis scientific awards at the Development (Hero of Development) Pharma (Leading Scientist) and Corporate (Distinguished Scientist) levels including Business Excellence awards. He is the only Novartis Physician-Scientist and only Clinician in Global Drug Development to be recognized twice (2014, Leading Scientist; 2016, Distinguished Scientist) with the prestigious Novartis VIVA (Vision, Innovation, Value and Achievement) Awards which represents the highest scientific achievement in Novartis.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Donor Stem Cell Drug

2 Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005561/en/